Last reviewed 2026-04-22 · How we verify

Bayesian Prediction Tacrolimus dosage

This is a Bayesian prediction tool for personalizing tacrolimus dosing based on individual patient pharmacokinetics, not a drug itself.

This is a Bayesian prediction tool for personalizing tacrolimus dosing based on individual patient pharmacokinetics, not a drug itself. Used for Optimization of tacrolimus dosing in transplant recipients and autoimmune disease patients.

At a glance

Mechanism of action

Bayesian prediction models use population pharmacokinetic data and individual patient characteristics to forecast tacrolimus blood concentrations and optimize dosing. This computational approach aims to achieve therapeutic drug levels more rapidly and accurately than standard dosing, reducing the need for frequent therapeutic drug monitoring adjustments. The tool is applied to tacrolimus, a calcineurin inhibitor immunosuppressant.

Approved indications

• Optimization of tacrolimus dosing in transplant recipients and autoimmune disease patients

Common side effects

No common side effects on file.

Key clinical trials

• Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation. (PHASE4)
• OPTImization of the Dose of tacroliMUS by Bayesian Prediction (PHASE4)
• Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bayesian Prediction Tacrolimus dosage CI brief — competitive landscape report
• Bayesian Prediction Tacrolimus dosage updates RSS · CI watch RSS
• NURIA LLOBERAS BLANCH portfolio CI